Abstract
Purpose
In the present study, the nonclinical safety profile of tolvaptan was evaluated.
Methods
A series of safety pharmacology and toxicology studies were performed in vitro and in mice, rats, dogs, rabbits and guinea pigs.
Results
In safety pharmacological studies, tolvaptan had no adverse effects on the central nervous, somatic nervous, autonomic nervous, smooth muscle, respiratory and cardiovascular, or digestive systems. In general toxicity studies, a single dose of tolvaptan up to 2,000 mg/kg was not lethal in rats and dogs. Tolvaptan did not cause any target organ toxicity in rats after treatment for 26 weeks or in dogs after treatment for 52 weeks at oral doses of up to 1,000 mg/kg/day. The toxicities observed in the present studies were generally attributable to the exaggerated pharmacological action of tolvaptan. In reproductive and developmental toxicity studies in rats, fertility was not affected. Suppressed viability or growth observed in the prenatal and postnatal progeny occurred at the maternally toxic dose of 1,000 mg/kg/day. In rabbits, tolvaptan showed teratogenicity at 1,000 mg/kg/day, a dose that was maternally toxic causing abortion. Tolvaptan was not genotoxic or carcinogenic, and did not induce phototoxicity, antigenicity or immunotoxicity.
Conclusion
Nonclinical toxicity that precludes the safe administration of tolvaptan to humans was not observed. However, appropriate cautions should be taken in women of childbearing potential.
Similar content being viewed by others
References
Kondo K, Ogawa H, Yamashita H, et al. 7-Chloro-5hydroxy-1[2-methyl-4-(2-methylbenzoyl-amino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist. Bioorg Med Chem. 1997;7:1743–54.
Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860–7.
Hirano T, Yamamura Y, Nakamura S, Onogawa T, Mori T. Effects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther. 2000;292:288–94.
Irwin S. Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia. 1968;13:222–57.
Takagi H, Inukai T, Nakama M. A modification of Haffner’s method for testing analgesics. Jpn J Pharmacol. 1966;16:287–94.
Courvoisier S, Ducrot R, Julou L. In: Garattini S, Ghetti V, editors. Psychotropic drugs. Amsterdam: Elsevier Publishing Co; 1957. p. 373.
Nishimura H, Miyamoto S. Teratogenic effects of sodium chloride in mice. Acta Anat (Basel). 1969;74:121–4.
Watanabe T, Endo A. Teratogenic effects of avidin-induced biotin deficiency in mice. Teratology. 1984;30:91–4.
Watanabe T. Dietary biotin deficiency affects reproductive function and prenatal development in hamsters. J Nutr. 1993;123:2101–8.
Disclosures
None of the authors have any conflicts of interest associated with this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Oi, A., Morishita, K., Awogi, T. et al. Nonclinical Safety Profile of Tolvaptan. Cardiovasc Drugs Ther 25 (Suppl 1), 91–99 (2011). https://doi.org/10.1007/s10557-011-6356-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10557-011-6356-y